CBG Shows Promise Against Rheumatoid Arthritis in New Research

Cannabigerol (CBG), a non-intoxicating cannabinoid, has emerged as a promising candidate for treating rheumatoid arthritis based on new preclinical research. Scientists tested CBG in rheumatoid arthritis models and observed encouraging results regarding its anti-inflammatory properties. While these findings represent an important step forward in understanding cannabinoid therapeutics, researchers emphasize the work remains in early stages and is not yet ready for clinical application in patients. The study adds CBG to a growing body of evidence suggesting minor cannabinoids may offer therapeutic potential beyond THC and CBD. Further clinical trials will be necessary before CBG-based treatments could become available to arthritis patients.